Checkmate Pharmaceuticals was a clinical-stage biopharmaceutical company dedicated to developing proprietary oligonucleotides to activate the innate immune system and harness its power to combat cancer. Their leading product candidate, vidutolimod (CMP-001), a Toll-like receptor 9 (TLR9) agonist delivered as a biologic virus-like particle (VLP), aimed to sensitize tumors to checkpoint inhibitors and other cancer therapies by triggering a robust anti-tumor T cell response. In May 2022, Checkmate Pharmaceuticals was acquired by Regeneron Pharmaceuticals, integrating its promising assets into Regeneron's oncology portfolio.
The Cambridge headquarters served as the central nexus for all company operations, including research and development, clinical trial management, corporate strategy, and administrative functions.
Located within the Kendall Square area, known for its high concentration of life science companies and research institutions, providing access to state-of-the-art facilities and a rich talent ecosystem.
Characterized by a scientifically driven, innovative, and collaborative environment, with a strong focus on a patient-centric mission to develop transformative cancer therapies. It was likely a dynamic and fast-paced setting typical of clinical-stage biotech firms.
The Cambridge location was strategically important, offering proximity to leading academic research, potential collaborators, and a skilled workforce, crucial for a company in the competitive field of cancer immunotherapy.
As a clinical-stage biopharmaceutical company, Checkmate Pharmaceuticals's global presence was primarily manifested through its international clinical trial sites and collaborations. While its operational hub was in the United States, the development of its oncology pipeline, particularly vidutolimod, involved engaging with investigators, research institutions, and patient populations across multiple countries. Following its acquisition, its assets contribute to Regeneron's established global operational and commercial footprint.
245 Main Street, Suite 500
Cambridge
Massachusetts
USA
Address: N/A
All core corporate, research, and development operations were largely consolidated at the main headquarters to ensure cohesive strategy and execution.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Checkmate Pharmaceuticals' leadership includes:
Checkmate Pharmaceuticals has been backed by several prominent investors over the years, including:
The most significant executive event for Checkmate Pharmaceuticals was its acquisition by Regeneron Pharmaceuticals in May 2022. This event led to the transition of its entire executive leadership team as the company was integrated into Regeneron. There were no major publicly announced new hires to the independent Checkmate executive team in the 12 months leading up to the acquisition.
Discover the tools Checkmate Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Regeneron, Checkmate Pharmaceuticals likely utilized standard corporate email formats. Common structures include [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com]. These formats are provided for historical reference as the checkmatepharma.com domain is no longer active for email.
[first_initial][last]@checkmatepharma.com or [first].[last]@checkmatepharma.com
Format
jdoe@checkmatepharma.com
Example
0%
Success rate
Regeneron Pharmaceuticals • May 19, 2022
Regeneron Pharmaceuticals, Inc. announced the successful completion of its acquisition of Checkmate Pharmaceuticals, Inc. This acquisition brings Checkmate's expertise in harnessing the immune system to combat cancer, notably its lead candidate vidutolimod, into Regeneron's portfolio....more
GlobeNewswire (PR Newswire) • April 19, 2022
Regeneron Pharmaceuticals and Checkmate Pharmaceuticals announced a definitive agreement for Regeneron to acquire Checkmate for $10.50 per share in cash. The acquisition aimed to add Checkmate's vidutolimod, an investigational TLR9 agonist, to Regeneron's growing oncology pipeline....more
GlobeNewswire • March 1, 2022
Checkmate Pharmaceuticals reported its financial results for Q4 and full-year 2021, providing updates on its clinical programs, including ongoing trials for vidutolimod in melanoma and non-small cell lung cancer, and outlining its strategic priorities for advancing its pipeline....more
GlobeNewswire • November 9, 2021
Checkmate Pharmaceuticals announced its Q3 2021 financial results and provided an update on its clinical development programs, emphasizing the progress of vidutolimod (CMP-001) in combination therapies for various cancers....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Checkmate Pharmaceuticals, are just a search away.